We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image
  • Published On : Jun 2020
  • Code : CMI24
  • Pages :155
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Business process outsourcing (BPO) is the contracting of non-primary business activities and functions to a third-party provider. Life sciences offers various services in research, discovery, development, drug registration, and product launch.    

Statistics:

The global life sciences BPO market is estimated to account for US$ 667.3Bn in terms of value by the end of 2027.

Global Life Sciences BPO Market: Drivers

Increasing cost of drug development is expected to propel growth of the global life sciences BPO market over the forecast period. For instance, the cost of drug development was US$ 2.6 billion, which included average out-of-pocket costs of US$ 1.4 billion and time costs of US$ 1.2 billion, according to a study by the Tufts Center for the Study of Drug Development published in the Journal of Health Economics in May 2019.

Moreover, patent expiration is also expected to aid in growth of the market. For instance, patent for YAZ (drospirenone/ethinylestradiol), which provides an oral contraceptive regimen, is set to expire in 2021. 

Statistics:

Asia Pacific held dominant position in the global life sciences BPO market in 2019, accounting for 39.9% share in terms of volume, followed by North America and Europe, respectively

Figure 1: Global Life Sciences BPO Market Share (%) Value, By Region, 2019

LIFE SCIENCES BPO MARKET

To learn more about this report, request a free sample copy

Global Life Sciences BPO Market: Restraints

Data safety concerns are expected to hinder growth of the global life sciences BPO market. Despite growing adoption of contract research outsourcing process, pharmaceutical companies still consider reliability of the service provider a major challenge as there have been many cases of data breach in the past.

Moreover, stringent and varied regulatory approval processes in different countries are also expected to limit the market growth. Majority of the clinical trials and other research processes are outsourced to various countries simultaneously. These destination countries have different guidelines and regulatory processes related to drugs, filing and clinical trials. The conduction of multi-location trials of a single drug in different procedures in different countries poses a challenge to pharmaceutical companies as they have to follow a completely different procedure in each country.

Life Sciences BPO Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 222.9 Bn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 14.7% 2027 Value Projection: US$ 667.3 Bn
Geographies covered:
  • North America: U.S., Canada
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, U.K., France, Spain, Italy, Russia, Rest of Europe
  • Asia Pacific: China, Japan, India, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, Rest of Middle East
  • Africa: North Africa, Central Africa, South Africa
Segments covered:
  • By Service Type:
    • CMO: API Manufacturing, Final dosage form manufacturing, Packaging
    • CRO: Drug Discovery, Preclinical studies, Early Phase I - IIa, Phase IIa - III, Phase IIIb - IV, Medical writing, Pharmcovigilance, Monitoring, Clinical Data Management, Regulatory services, Bio-statistics, Site management, Protocol development, Others
Companies covered:

Accenture, Plc., Boehringer Ingelheim GmbH, Charles River Laboratories International, Inc., Cognizant Technology Solutions, Covance, Inc., DSM, Fareva, ICON, Plc, Infosys, Catalent, Inc., Genpact Limited, Health Decisions, Inc., and ProMab Biotechnologies, Inc.

Growth Drivers:
  • Increasing prevalence of chronic disorders
Restraints & Challenges:
  • Data safety issues

Global Life Sciences BPO Market: Opportunities

R&D in cell therapies is expected to offer lucrative growth opportunities for players in the global life sciences BPO market over the forecast period. For instance, in February 2020, Caribou Biosciences, Inc., a CRISPR genome editing company, signed a sale and assignment agreement with ProMab Biotechnologies, Inc., a biotechnology CRO/CDMO specializing in antibody engineering and CAR-T development, under which Caribou gains access to a ProMab humanized single-chain variable fragment (scFv) targeting the B-cell maturation antigen for use in allogeneic engineered cell therapies.  

Moreover, increasing prevalence of chronic disorders is also expected to aid in growth of the market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.

Statistics:

The global life sciences BPO market was valued at US$ 222.9 Bn in 2019 and is forecast to reach a value of US$ 667.3 Bn by 2027 at a CAGR of 14.7% between 2020 and 2027.

Figure 2: Global Life Sciences BPO Market Value (US$ Bn), 2016 – 2027

LIFE SCIENCES BPO MARKET

To learn more about this report, request a free sample copy

Market Trends/Key Takeaways

Major players in the market are focused on acquiring public contracts to enhance their market share. For instance, in April 2020, Accenture Federal Services, a subsidiary of Accenture, Plc, received a US$ 96 million task order to help the U.S. Department of Veterans Affairs provide consumer-grade IT and mission service experiences.

Major players in the market are also focused on adopting partnership strategies to enhance their market share. For instance, in May 2020, Boehringer Ingelheim signed a licensing agreement with CDR-Life for to R&D of antibody fragment-based therapeutics for geographic atrophy.

Global Life Sciences BPO Market: Competitive Landscape

Major players operating in the global Life Sciences BPO market include, Accenture, Plc, Boehringer Ingelheim GmbH, Charles River Laboratories International, Inc., Cognizant Technology Solutions, Covance, Inc., DSM, Fareva, ICON, Plc, Infosys, Catalent, Inc., Genpact Limited, Health Decisions, Inc., and ProMab Biotechnologies, Inc.

Global Life Sciences BPO Market: Key Developments

Major players in the market are focused on adopting M&A strategies to expand their product portfolio. For instance, in May 2020, Catalent, Inc. announced a deal to acquire a clinical packaging facility in Minakuchi, Japan, from Teva-Takeda Pharmaceuticals in order to establish a new clinical GMP manufacturing and distribution hub to support clinical studies.

?Major players in the market are also focused on adopting partnership strategies to enhance their market share. For instance, in March 2020, Charles River Laboratories International, Inc. partnered with Deciphex, a preclinical digital pathology software-as-a-service provider, to enhance drug discovery & development with digital pathology.

Frequently Asked Questions

The Global Life Sciences BPO market size was valued at US$ 222.9 billion in 2019 and is estimated to exhibit a CAGR of 14.7% between 2020 and 2027.

CMO segment held the major market share in 2019 owing to an increasing prevalence of chronic disorders is expected to propel growth of the market.

Major factor driving the growth of Global Life Sciences BPO market during the forecast period increasing prevalence of chronic disorders, increasing research & development for novel drug product , and adoption of expansion strategies from major companies.

Major factors hampering the growth of the Global Life Sciences BPO market during the forecast period constitutes of data safety concerns are expected to hinder growth of the market.

Asia Pacific market is expected to generate the highest revenue during the forecast period.

Some of the key players operating in the market are Accenture, Plc, Boehringer Ingelheim GmbH, Charles River Laboratories International, Inc., Cognizant Technology Solutions, Covance, Inc., DSM, Fareva, ICON, Plc, Infosys, Catalent, Inc., Genpact Limited, Health Decisions, Inc., and ProMab Biotechnologies, Inc.

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount
Logo

Reliability and Reputation

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Reliability and Reputation

27001:2022

Reliability and Reputation

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo